Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Leoclan CoTSE:7681 66 Piotroski F-Score is 4 as of Aug. 03, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates TSE:7681 with a GF Score™ of 66/100 and a GF Value™ of 円1,290.91 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 114 Medical Distribution companies, Leoclan Co ranks worse than 64.04% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Leoclan Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Leoclan Co's Piotroski F-Score or its related term are showing as below:
TSE:7681'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 6 Max: 8
Current: 4
During the past 9 years, the highest Piotroski F-Score of Leoclan Co was 8. The lowest was 4. And the median was 6.
Leoclan Co (TSE:7681) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Leoclan Co Piotroski F-Score Related Terms
Leoclan Co Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Leoclan Co's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7681 vs MCK, COR, CAH: Piotroski F-Score Comparison
For the Medical Distribution subindustry, Leoclan Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leoclan Co Piotroski F-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Leoclan Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Leoclan Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Leoclan Co's current Net Income (TTM) was 153.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Leoclan Co's return on assets of this year was 0.01433228. Leoclan Co's return on assets of last year was 0.0092594.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Leoclan Co's current ratio of this year was 2.23169031. Leoclan Co's current ratio of last year was 2.41565174.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Leoclan Co's number of shares in issue this year was 5.931. Leoclan Co's number of shares in issue last year was 5.926.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Leoclan Co's gross margin of this year was 0.12759006. Leoclan Co's gross margin of last year was 0.13223895.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Leoclan Co's asset turnover of this year was 2.01596985. Leoclan Co's asset turnover of last year was 1.34778356.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
0
+
1
+
0
+
1
+
0
+
0
+
0
+
1
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Leoclan Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Leoclan Co (TSE:7681) has a Piotroski F-Score of 4 as of Aug. 03, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Leoclan Co and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Leoclan Co's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Leoclan Co ranks #73 out of 114 companies in the Medical Distribution industry, placing it in the top 64%.
Is Leoclan Co's Piotroski F-Score too high?
Leoclan Co's current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Medical Distribution industry median Piotroski F-Score is 5.00. Leoclan Co's value of 4 is 20% below this industry median. Based on the distribution chart, Leoclan Co ranks #73 out of 114 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Leoclan Co has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Leoclan Co's Piotroski F-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Leoclan Co ranks #73 out of 114 companies for Piotroski F-Score. This places Leoclan Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Leoclan Co's value of 4 is 20% below this benchmark. Historically, Leoclan Co's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Leoclan Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Leoclan Co's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Leoclan Co and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Leoclan Co's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Leoclan Co stock overvalued right now?
Based on GuruFocus' analysis, Leoclan Co (TSE:7681) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,290.91, compared to a current price of 円955.00 — trading 26% below its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 20% below the Medical Distribution industry median of 5.00. Leoclan Co's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Leoclan Co (TSE:7681), the current Piotroski F-Score is 4 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Leoclan Co (TSE:7681) Overvalued in 2026?
Based on GuruFocus' analysis, Leoclan Co stock appears to be undervalued.
The current stock price of 円955.00 is trading 26% below its estimated GF Value™ of 円1,290.91.
GuruFocus considers Leoclan Co to be Modestly Undervalued.
Key valuation signals for TSE:7681:
Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
GF Value™: 円1,290.91 vs. price of 円955.00 (26% below fair value)
Industry Position: 20% below the Medical Distribution median (#73 of 114)
No single metric tells the full story. See the TSE:7681 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7681 has been successfully added to your 
